Cytosorbents Corporation

Good afternoon and welcome to the CIDAL-Sorbent First Quarter 2023 Financial and Operating Results Conference Call. At this time, all participants are in a listen-only mode. Following the formal remarks, we will open the call for your questions. Please be advised that the call will be recorded at the company's request. At this time, I would like to turn the call over to our moderator, Taylor Devlin. Please go ahead, Taylor.

Thank you and good afternoon. Welcome to Cytosorbent's First Quarter 2023 Financial and Operating Results Conference Call. Joining me today from the company are Dr. Philip Chan, Chief Executive Officer, Vincent Caponi, President and Chief Operating Officer, Kathleen Block, Interim Chief Financial Officer, Dr. Estimios Deliagiris, Chief Medical Officer, Dr. Christian Steiner, Executive Vice President of Sales and Marketing and Managing Director of Cytosurbans Europe, GMBH, Christopher Kramer, Senior Vice President of Business Development, and Dr. Irina Kulinets, Senior Vice President of Regulatory. Before I turn the call over to Dr. Chan, I'd like to remind listeners that during the call, management's prepared remarks may contain forward looking statements which are subject to risks and uncertainties. Management may make additional forward looking statements in response to your questions today. Therefore, the company claims protection under safe harbor for forward looking statements contained in the Private Securities Litigation Reform Act of 1995. Actual results may differ from results discussed today and therefore we refer you to a more detailed discussion of these risks and uncertainties in the company's filings with the SEC. Any projections as to the company's future performance represented by management include estimates today as of May 2, 2023, and we assume no obligation to update these projections in the near future as market conditions change. During today's call, We will have an overview presentation covering the operating and financial highlights for the first quarter of 2023 by Dr. Chan and Ms. Block. Following that presentation, we will open the line to your questions during the live Q&A session with the rest of the management team. And now, it's my pleasure to turn the call over to Dr. Philip Chan.

Thank you very much, Taylor, and good afternoon, everyone. First of all, it's my pleasure to be here today to discuss some of our recent operating highlights.